Pharmacokinetics and steady-state tissue distribution of L- and D-isomers of nitroarginine in rats

Drug Metabolism and Disposition

Volumn 24, Issue 11, 1996, Pages 1241-1246

  Tabrizi Fard, Mohammad A ^a   Fung, Ho Leung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) NITRO DEXTRO ARGININE; N(G) NITROARGININE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; ISOMER; KIDNEY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; STEADY STATE; TESTIS;

ANIMALS; ENZYME INHIBITORS; ISOMERISM; MALE; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0030457690     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. S. Moncada and A. Higgs: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9, 1319-1330 (1995).
2. J. Zhang and S. H. Snyder: Nitric oxide in the nervous system. Annu. Rev. Pharmacol. 35, 213-233 (1995).
3. R. M. J. Palmer and S. Moncada: A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem. Biophys. Res. Commun. 158, 384-352 (1989).
4. M. A. Marletta: Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78, 927-930 (1994).
5. U. Frostermann, E. I. Closs, J. S. Pollock, M. Nakane, P. Schwarz, I. Gath, and H. Kleinert: Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 23, 1121-1131 (1994).
6. S. Moncada, R. M. J. Palmer, and A. Higgs: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-141 (1991).
7. J. A. Lorente, L. Landin, R. D. Pablo, E. Renes, and D. Liste: L-Arginine pathway in the sepsis syndrome. Crit. Care Med. 21, 1287-1295 (1993).
8. A. Petros, G. Lamb, A. Leone, S. Moncada, D. Bennett, and P. Vallance: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28, 34-39 (1994).
9. D. D. Rees, R. M. J. Palmer, R. Schulz, H. F. Hodson, and S. Moncada: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol 101, 746-752 (1990).
10. H. M. Vargas, J. M. Cuevas, L. J. Ignarro, and G. Chaudhuri: Comparison of the inhibitory potencies of N-methyl-, N-nitro-, and N-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. J. Pharmacol. Exp. Ther. 257, 1208-1215 (1991).
11. S. S. Gross, D. J. Stuehr, K. Aisaka, E. A. Jaffe, R. Levi, and O. W Griffith: Macrophage and endothelial cell nitric oxide synthesis: cell-type selective inhibition by N-aminoarginine, N-nitroarginine, and N-methylarginine. Biochem. Biophys. Res. Commun. 170, 96-103 (1990).
12. G. R. Martin, M. L. Bolofo, and H. Giles: Inhibition of endothelium-dependent vasorelaxation by arginine analogues: a pharmacological analysis of agonist and tissue dependence. Br. J. Pharmacol. 105, 643-652 (1992).
13. G. A. Joly, M. Ayres, F. Chelly, and R. G. Kilbourn: Effects of N-methyl-L-arginine. N-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem. Biophys. Res. Commun. 199, 147-154 (1994).
14. R. G. Bogle, S. Moncada, J. D. Pearson, and G. E. Mann: Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter. Br. J. Pharmacol. 105, 768-770 (1992).
15. K. Schmidt, P. Klatt, and B. Mayer: Characterization of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors. Mol. Pharmacol. 44, 615-621 (1993).
16. G. Guidotti, A. Borghetti, and G. C. Gazzola: The regulation of amino acid transport in animal cells. Biochem. Biophys. Acta 515, 329-366 (1978).
17. M. A. Tabrizi-Fard and H. L. Fung: A reversed-phase HPLC method for the analysis of nitro-arginine in rat plasma and urine. J. Chromatogr. B Biomed. Appl. 679, 7-12 (1996).
18. J. G. Wagner: A safe method for rapidly achieving plasma concentration plateaus. Clin. Pharmacol. Ther. 16, 691-700 (1974).
19. M. L. Rocci, Jr. and W. J. Jusko: Lagran program for area and moments in pharmacokinetic analysis. Com. Pro. Biom. 16, 203-216 (1983).
20. J. W. T. Dickerson and E. M. Widdowson: Chemical changes in skeletal muscle during development. Biochem. J. 74, 247-257 (1960).
21. A. J. Creskoff, T. Fitz-Hugh, and E. J. Farris: Hematology of the rat: methods and standards. In "The Rat in Laboratory Investigation" (E. J. Farris and J. Q. Griffin, eds.), pp. 406-413. Haffner Publishing Co., New York, 1963.
22. M. A. Tabrizi-Fard and H. L. Fung: Pharmacokinetics, plasma protein binding and urinary excretion of N-nitro-L-arginine in rats. Br. J. Pharmacol 111, 394-396 (1994).
23. S. Bachmann, H. M. Bosse, and P. Mundel: Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am. J. Physiol 268, F885-898 (1995).
24. L. Kobzik, M. B. Reid, D. S. Bredt, and J. S. Stamler: Nitric oxide in skeletal muscle. Nature 372, 546-548 (1994).
25. L. Kobzik, B. Stringer, J. L. Balligand, M. B. Reid, and J. S. Stamler: Endothelial type nitric oxide synthase in skeletal muscle fibers: mitochondrial relationships. Biochem. Biophys. Res. Commun. 211, 375-381 (1995).
26. M. Nakane, H. H. Schmidt, J. S. Pollack, U. Forstermann, and F. Murad: Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett. 316, 175-180 (1993).
27. R. Konno and Y. Yasumura: D-Amino-acid oxidase and its physiological function. Int. J. Biochem. 24, 519-524 (1992).
28. M. Dixon and K. Kleppe: D-Amino acid oxidase. II. Specificity, competitive inhibition and reaction sequence. Biochem. Biophys. Acta 96, 368-382 (1965).
29. Y. Nagata, R. Kono, Y. Yasumura, and T. Akino: Involvement of D-amino acid oxidase in elimination of free D-amino acids in mice. Biochem. J. 257, 291-292 (1989).
30. R. Konno, K. Isobe, A. Niwa, and Y. Yasumura: Lack of D-amino-acid oxidase activity causes a specific renal aminoaciduria in the mouse. Biochem. Biophys. Acta 967, 382-390 (1988).
31. A. Buisson, M. Plotkine, and R. G. Boulu: The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischemia. Br. J. Pharmacol. 106, 766-767 (1992).
32. A. Buisson, I. Margaill, J. Callbert, M. Plotkine, and R. G. Boulu: Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J. Neurochem. 61, 690-696 (1993).
33. Y. A. Kolesnikov, C. G. Pick, G. Ciszewska, and G. W. Pasternak: Blockade of tolerance to morphine but not to k opiods by a nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 90, 5162-5166 (1993).
34. D. W. Reif and S. A. McCreedy: N-Nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases. Arch. Biochem. Biophys. 320, 170-176 (1995).